<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=22848"><dc:title>Hymenoptera venom immunotherapy in dogs</dc:title><dc:creator>Rostaher,	Ana	(Avtor)
	</dc:creator><dc:creator>Fischer,	Nina Maria	(Avtor)
	</dc:creator><dc:creator>Vigani,	Alessio	(Avtor)
	</dc:creator><dc:creator>Šteblaj,	Barbara	(Avtor)
	</dc:creator><dc:creator>Martini,	Franco	(Avtor)
	</dc:creator><dc:creator>Brem,	Salina	(Avtor)
	</dc:creator><dc:creator>Favrot,	Claude	(Avtor)
	</dc:creator><dc:creator>Košnik,	Mitja	(Avtor)
	</dc:creator><dc:subject>anaphylaxis</dc:subject><dc:subject>angioedema</dc:subject><dc:subject>dogs</dc:subject><dc:subject>Hymenoptera allergy</dc:subject><dc:subject>urticaria</dc:subject><dc:subject>venom immunotherapy</dc:subject><dc:description>Insect venom allergy is a potentially life-threatening allergic reaction following a bee, wasp, or ant sting. The only treatment to prevent further systemic sting reactions is venom immunotherapy (VIT), with an efficacy of up to 98% in humans. Prospective clinical data on VIT efficacy in dogs are currently lacking. In this investigation, 10 dogs with severe allergic reactions to either bee or wasp stings were treated with VIT. All dogs tolerated the therapy without adverse effects and the dogs which were re-stung tolerated the sting. This means that VIT is not only safe, but also efficacious in these patients. Furthermore, it was also shown that in addition to skin testing, two serum allergen-specific IgE tests were reliable to identify the underlying patients’ insect sensitization pattern.</dc:description><dc:publisher>MDPI AG, 2013-</dc:publisher><dc:date>2023</dc:date><dc:date>2025-07-03 10:16:39</dc:date><dc:type>Neznano</dc:type><dc:identifier>22848</dc:identifier><dc:source>Animals </dc:source><dc:language>sl</dc:language><dc:rights>© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).</dc:rights></rdf:Description></rdf:RDF>
